Joseph Mikhael, MD, and Peter Voorhees, MD, discuss frontline therapy for multiple myeloma and new options for both transplant-eligible and transplant-ineligible patients.
Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/964337). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
International Myeloma Foundation https://www.myeloma.org/
Lenalidomide, Bortezomib, and Dexamethasone (RVD) Regimen for Multiple Myeloma https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278911/pdf/i0018-5787-52-1-27.pdf
Carfilzomib, Lenalidomide, and Dexamethasone Plus Transplant in Newly Diagnosed Multiple Myeloma https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714092/
Maintenance With Daratumumab or Observation Following Treatment With Bortezomib, Thalidomide, and Dexamethasone With or Without Daratumumab and Autologous Stem-Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma (CASSIOPEIA): An Open-Label, Randomised, Phase 3 Trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00428-9/fulltext
Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone for Transplant-Eligible Newly Diagnosed Multiple Myeloma: The GRIFFIN Trial https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and
Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of GRIFFIN After 24 Months of Maintenance https://ash.confex.com/ash/2021/webprogram/Paper149024.html
Venetoclax or Placebo in Combination With Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (BELLINI): A Randomised, Double-Blind, Multicentre, Phase 3 Trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30525-8/fulltext
Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial https://ash.confex.com/ash/2021/webprogram/Paper145097.html
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma https://ascopubs.org/doi/10.1200/JCO.21.01935
Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma Without Intention for Immediate Autologous Stem-Cell Transplantation (ENDURANCE): A Multicentre, Open-Label, Phase 3, Randomised, Controlled Trial https://www.thelancet.com/article/S1470-2045(20)30452-6/fulltext
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma The MANHATTAN Nonrandomized Clinical Trial https://jamanetwork.com/journals/jamaoncology/fullarticle/2778195
Carfilzomib or Bortezomib in Relapsed or Refractory Multiple Myeloma (ENDEAVOR): An Interim Overall Survival Analysis of an Open-Label, Randomised, Phase 3 Trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30578-8/fulltext
Carfilzomib With Cyclophosphamide and Dexamethasone or Lenalidomide and Dexamethasone Plus Autologous Transplantation or Carfilzomib Plus Lenalidomide and Dexamethasone, Followed by Maintenance With Carfilzomib Plus Lenalidomide or Lenalidomide Alone for Patients With Newly Diagnosed Multiple Myeloma (FORTE): A Randomised, Open-Label, Phase 2 Trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00535-0/fulltext
Lenalidomide, Bortezomib, and Dexamethasone With Transplantation for Myeloma https://www.nejm.org/doi/full/10.1056/NEJMoa1611750